United States · FDA National Drug Code directory
Rituxan Hycela
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 50242-109_e8a259ac-2a09-4026-823c-f23cbcba6a2b
- Product NDC
- 50242-109
- Form
- INJECTION, SOLUTION
- Composition / generic term
- rituximab and hyaluronidase
- Labeler
- Genentech, Inc.
- Marketing category
- BLA
- Marketing start / end (source format)
- 20170622
- Source listing expiry
- 20261231
Source-listed ingredients
- RITUXIMAB — 120 mg/mL
- HYALURONIDASE (HUMAN RECOMBINANT) — 2000 U/mL
These values do not establish equivalence or a dose recommendation.
Packages
- 1 VIAL, SINGLE-DOSE in 1 CARTON (50242-109-01) / 13.4 mL in 1 VIAL, SINGLE-DOSE · 50242-109-01
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →